Details for New Drug Application (NDA): 208840
✉ Email this page to a colleague
NDA 208840 describes TRANEXAMIC ACID, which is a drug marketed by Am Regent, Amneal Pharms Co, Apotex, Avet Lifesciences, Caplin, Chartwell Rx, Epic Pharma Llc, Eugia Pharma, Fresenius Kabi Usa, Gland, Heritage, Micro Labs, Mylan Institutional, Provepharm Sas, Rising, Xgen Pharms, Zydus Pharms, Amneal, Exela Pharma, Gland Pharma Ltd, Nexus, Actavis Labs Fl Inc, Ani Pharms, Aurobindo Pharma Usa, and Rubicon, and is included in twenty-eight NDAs. It is available from thirty-three suppliers. Additional details are available on the TRANEXAMIC ACID profile page.
The generic ingredient in TRANEXAMIC ACID is tranexamic acid. There are eight drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the tranexamic acid profile page.
The generic ingredient in TRANEXAMIC ACID is tranexamic acid. There are eight drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the tranexamic acid profile page.
Summary for 208840
| Tradename: | TRANEXAMIC ACID |
| Applicant: | Amneal Pharms Co |
| Ingredient: | tranexamic acid |
| Patents: | 0 |
Pharmacology for NDA: 208840
| Physiological Effect | Decreased Fibrinolysis |
Medical Subject Heading (MeSH) Categories for 208840
Suppliers and Packaging for NDA: 208840
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TRANEXAMIC ACID | tranexamic acid | INJECTABLE;INJECTION | 208840 | ANDA | Amneal Pharmaceuticals LLC | 70121-1398 | 70121-1398-1 | 1 VIAL, SINGLE-DOSE in 1 CARTON (70121-1398-1) / 10 mL in 1 VIAL, SINGLE-DOSE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 100MG/ML | ||||
| Approval Date: | Feb 28, 2017 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
